Biomet Announces Senior Management Changes
July 12 2006 - 10:28AM
Business Wire
Biomet, Inc. (NASDAQ:BMET) today announced that Charles E. Niemier
has been appointed as President of EBI's operations following the
resignation of Bart J. Doedens, M.D., former President of EBI, who
has decided to pursue other interests. Mr. Niemier has been a
member of senior management and the Board of Directors of Biomet
for more than 25 years and has served in a variety of operational
roles with Biomet during his tenure including Chief Financial
Officer and, more recently, Chief Operating Officer - International
Operations. Additionally, Robert Phelps has been promoted to Vice
President-Sales at EBI. Mr. Phelps has over 25 years of experience
in the orthopedic industry with Johnson & Johnson and most
recently with Biomet as its Area Vice President,
Northeast/Mid-Atlantic Sales. Joe Milano has joined EBI as its Vice
President, Finance and Administration. Mr. Milano was most recently
Executive Vice President and CFO for Aircast. Biomet's Interim
President and Chief Executive Officer, Daniel P. Hann, commented,
"We are pleased to announce the appointment of Mr. Niemier as
President of EBI. We are confident that Mr. Niemier will provide
the leadership capabilities necessary to position EBI as a leader
in the spinal and fixation market places, and improve our
leadership position in electrical stimulation. Additionally, the
senior management team at EBI has been significantly strengthened
with the additions of both Mr. Phelps and Mr. Milano in the key
areas of sales management and finance." Biomet, Inc. and its
subsidiaries design, manufacture and market products used primarily
by musculoskeletal medical specialists in both surgical and
non-surgical therapy. The Company's product portfolio encompasses
reconstructive products, including orthopedic joint replacement
devices, bone cements and accessories, and dental reconstructive
implants; fixation products, including electrical bone growth
stimulators, internal and external orthopedic fixation devices,
craniomaxillofacial implants and bone substitute materials; spinal
products, including spinal stimulation devices, spinal hardware and
orthobiologics; and other products, such as arthroscopy products
and softgoods and bracing products. Headquartered in Warsaw,
Indiana, Biomet and its subsidiaries currently distribute products
in more than 100 countries. For further information contact Greg W.
Sasso, Senior Vice President, Corporate Development and
Communications at (574) 372-1528 or Barbara Goslee, Manager,
Corporate Communications at (574) 372-1514. This press release
contains certain statements that are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, as amended,
such as the Company's estimated results. Although the Company
believes that the assumptions, on which the forward-looking
statements contained herein are based, are reasonable, any of those
assumptions could prove to be inaccurate given the inherent
uncertainties as to the occurrence or non-occurrence of future
events. In particular, the Company cautions the reader that the
results discussed herein are only estimates, and that new or
additional information could cause such results to differ
materially. There can be no assurance that the forward-looking
statements contained in this press release will prove to be
accurate. Some of the factors that could cause actual results to
differ from those contained in forward-looking statements made in
this press release include the success of the Company's principal
product lines, the Company's ability to develop and market new
products and technologies in a timely manner, government
regulation, currency exchange rate fluctuations, reimbursements
from third party payors, litigation, revenue and earnings
estimates, and other risk factors as set forth from time to time in
the Company's filings with the SEC. The inclusion of a
forward-looking statement herein should not be regarded as a
representation by the Company that the Company's objectives will be
achieved. The Company undertakes no obligation to publicly update
forward-looking statements, whether as a result of new information,
future events or otherwise. All of Biomet's financial information
may be obtained on our website at www.biomet.com or you may contact
us by e-mail at investor.relations@biometmail.com.
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jul 2023 to Jul 2024